Aisling Capital Management as of March 31, 2024
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 16 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 63.5 | $188M | 6.1M | 30.92 | |
| Syndax Pharmaceuticals (SNDX) | 8.3 | $24M | 1.0M | 23.80 | |
| Verona Pharma Sponsored Ads (VRNA) | 6.1 | $18M | 1.1M | 16.09 | |
| Elevation Oncology (ELEV) | 4.9 | $15M | 2.8M | 5.13 | |
| Biomea Fusion (BMEA) | 4.0 | $12M | 799k | 14.95 | |
| Monte Rosa Therapeutics (GLUE) | 3.5 | $10M | 1.5M | 7.05 | |
| Nuvation Bio Com Cl A (NUVB) | 3.1 | $9.2M | 2.5M | 3.64 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.7 | $8.0M | 965k | 8.32 | |
| Poseida Therapeutics I (PSTX) | 1.1 | $3.3M | 1.0M | 3.19 | |
| Calcimedica (CALC) | 0.7 | $2.2M | 521k | 4.16 | |
| Reneo Pharmaceuticals (RPHM) | 0.5 | $1.5M | 886k | 1.66 | |
| Marker Therapeutics Com New (MRKR) | 0.5 | $1.4M | 314k | 4.30 | |
| Avrobio Ord (AVRO) | 0.4 | $1.3M | 1.0M | 1.28 | |
| Spruce Biosciences (SPRB) | 0.3 | $948k | 1.2M | 0.79 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $539k | 435k | 1.24 | |
| Viracta Therapeutics (VIRX) | 0.1 | $294k | 289k | 1.02 |
